Targeting IL-2 to tumor-specific T cells with novel biologic platforms

Time: 11:30 am
day: Day One


  • Generating a therapeutic index for IL-2 via selective delivery to tumor-specific T cells demonstrates anti-tumor activity in cancer patients
  • Lead clinical candidate, CUE-101, provides clinical PoC and de-risking for the Immuno-STAT platform
  • Novel bispecifics that can re-direct the protective viral T cell repertoire to destroy cancers – potential for superior safety and clinical efficacy